Capricor Therapeutics (NASDAQ:CAPR) Shares Down 4.7% - What's Next?

Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report)'s stock price traded down 4.7% during mid-day trading on Friday . The stock traded as low as $12.25 and last traded at $12.15. 363,080 shares were traded during mid-day trading, a decline of 76% from the average session volume of 1,502,834 shares. The stock had previously closed at $12.74.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. HC Wainwright reaffirmed a "buy" rating and issued a $77.00 price target on shares of Capricor Therapeutics in a research note on Monday, March 17th. Cantor Fitzgerald reissued an "overweight" rating and set a $30.00 price objective on shares of Capricor Therapeutics in a research report on Thursday, March 20th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $34.50.

Capricor Therapeutics Stock Performance

The company has a market cap of $316.72 million, a P/E ratio of -6.66 and a beta of 0.85. The business's fifty day moving average is $11.61 and its two-hundred day moving average is $14.47.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.15. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The business had revenue of $11.13 million for the quarter, compared to the consensus estimate of $9.87 million. Analysts expect that Capricor Therapeutics Inc will post -1.21 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Summit Investment Advisors Inc. grew its holdings in shares of Capricor Therapeutics by 54.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock worth $53,000 after buying an additional 1,345 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in Capricor Therapeutics by 172.8% during the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock worth $64,000 after acquiring an additional 2,947 shares in the last quarter. Virtus ETF Advisers LLC purchased a new position in shares of Capricor Therapeutics in the fourth quarter valued at approximately $68,000. AlphaQuest LLC acquired a new stake in shares of Capricor Therapeutics in the fourth quarter valued at $78,000. Finally, New York State Common Retirement Fund increased its stake in shares of Capricor Therapeutics by 625.0% during the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock worth $80,000 after buying an additional 5,000 shares during the period. Institutional investors and hedge funds own 21.68% of the company's stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.